PharmaTelevision - Kerstin Valinder explains Nycomed’s transformation from local Scandinavian company to Global Pharma Company

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Kerstin Valinder explains Nycomed’s transformation from local Scandinavian company to Global Pharma Company

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Kerstin Valinder, Vice President of Licensing at Nycomed

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Nycomed : Focus on emerging market and role as a global player

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here in Munich at BIO-Europe 2010. On this show I've got Kerstin Valinder, who is Executive Vice President of Business Development at Nycomed , welcome to the show.

Kerstin Valinder:

Thank you.

Fintan Walton:

Kerstin Valinder, Nycomed is a company that is very well known around the world, it's a company that is obviously based here in Europe often perceived to be a Northern European company, just before we start talking about your role as Business Development, what is the best way to describe Nycomed ?

Kerstin Valinder:

I would like to say that Nycomed is a rapidly changing company moving from it's Northern European heritage by a strong Central European presence now going into emerging markets as the primary growth driver going forward. So yes we are based in Europe, we are headquartered in Switzerland, we have still most of our income from Europe, but that is changing rapidly so this year we expect more than one third of our turnover to be in emerging markets five-years from now probably to 50, 60% may be more. So that is a big change.

Fintan Walton:

So, are you a regional player or are you a global player?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr.Fintan Walton is the Founder and CEO of PharmaVentures. After completing his doctoral research on the genetics of cell proliferation at the University of Michigan( US )and Trinity College (Dublin, Ireland ), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc(1982-1992).

Kerstin Valinder

Executive Vice President

Kerstin Valinder has over two decades of experience in the pharmaceutical industry. She joined Nycomed in 1999, having previously worked for Astra and AstraZeneca. She holds a degree in journalism from Gothenburg University, Sweden.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Nycomed

Nycomed is a privately owned, global pharmaceutical company with headquarters in Zurich, Switzerland. The company employs 12,000 associates worldwide and has affiliates in more than 50 countries. Nycomed has a strong presence in Europe and in the emerging markets in Russia/Commonwealth of Independent States, Asia and Latin America. Nycomed ranks 28th among global pharmaceutical companies and is the 16th largest provider of OTC medicines. Nycomed 's differentiated portfolio of branded medicines is focused on gastroenterology , respiratoryand inflammatory diseases , pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio. Nycomed has 16 manufacturing sites: 5 centre's of competence in Europe for global products as well as 11 production sites for regional products in fast-growing countries such as Brazil and Mexico. A major investment is being made in a new pharmaceutical plant in Russia, currently Nycomed 's biggest single market.